The coronavirus outbreak has exposed India’s vulnerability when it comes to sourcing crucial raw materials for medicines from China, which meets about 70 per cent of the country's bulk drugs, or active pharmaceutical ingredients (APIs), requirement.
As the Indian government scouts for options to deal with any potential scarcity that can arise in the near future, the country's oldest public sector pharma company, Hindustan Antibiotics (HAL), has submitted a proposal to the government to reduce dependence on China for fermentation-based bulk drugs, it is ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.